Synonyms: Olizumab, rhuMab-E25
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Description |
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research.
|
|---|---|
| In vivo |
Omalizumab (anti-IgE) is effective in controlling the allergic symptoms of allergic rhinitis by lowering inflammatory mediator CysLT levels of nasal lavage in an experimental allergic rhinitis model. |
| Animal Research | References |
| CAS No. | 242138-07-4 |
|---|---|
| Isotype | Human IgG1 |
| Application | Omalizumab (anti-IgE) |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20 mM Arg, pH 5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.